Last updated: 2026-09-09 04:53:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Compass Therapeutics, Inc. (CMPX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.21, with a market capitalisation of $428.61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.61 to $6.88. This page covers its latest market performance, valuation, price trends and company information.
$428.61M | |
$2.32 | |
$12.50 | |
$0.77 | |
$2.38 | |
2.16M | |
2.97M | |
-- | |
$6.88 | |
$1.61 | |
-- | |
-- |
Compass Therapeutics, Inc. (CMPX) last closed at $2.38 as of 2026-09-08 23:58:00, unchanged from the previous close of $2.38.
During the latest regular trading session, CMPX traded between $0.77 and $12.50, with a volume of 2.16M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Compass Therapeutics, Inc. (CMPX) moved from $2.52 to $2.21, representing a decline of 12.50% ($0.31).
The stock traded between $2.21 and $2.53 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.46 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 11.3%
CMPX is currently trading at $2.21, placing it 11.3% of the way from its 52-week low of $1.61 to its 52-week high of $6.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 39 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Compass Therapeutics, Inc. (CMPX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.